All lobbying filings

FERRING PHARMACEUTICALS, INC.

Lobbying for FERRING PHARMACEUTICALS, INC.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $220,000.00 expenses · posted Apr 18, 2026

Official filing document

Bills named in this filing 8

HR 8119
HOPE with Fertility Services Act
HR 1670
Family Building FEHB Fairness Act
S 797
Family Building FEHB Fairness Act
HR 220
Veterans Infertility Treatment Act of 2025
HR 6797
Bipartisan IVF for Military Families Act
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 1878
IVF Access and Affordability Act
HR 4639
Infertility Treatment Affordability Act of 2025

Lobbying activity 3

Health Issues

Issues related to fertility treatment, oncology and coverage, including: H.R. 8119, the HOPE with Fertility Services Act; H.R. 1670 and S. 797, the Family Building FEHB Fairness Act; H.R. 220, the Veterans Infertility Treatment Act; H.R. 6797, the Bipartisan IVF for Military Families Act; and H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act.

Taxation/Internal Revenue Code

Issues related to establishing a tax credit for fertility treatments, including: H.R. 1878, the IVF Access and Affordability Act; and H.R. 4639, the Infertility Treatment Affordability Act.

Trade (domestic/foreign)

Issues related to the treatment of pharmaceutical ingredients in trade agreements, including the United States-Argentina Agreement on Reciprocal Trade and Investment.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.